Literature DB >> 24406925

A cancer trial scandal and its regulatory backlash.

Razelle Kurzrock1, Hagop Kantarjian2, David J Stewart3.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24406925     DOI： 10.1038/nbt.2792

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  17 in total

1.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.

Authors:  Giannicola D'Addario; Melania Pintilie; Natasha B Leighl; Ronald Feld; Thomas Cerny; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

Review 2.  Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.

Authors:  C Monnerat; T Le Chevalier
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

3.  Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.

Authors:  David R Spigel; John D Hainsworth; John H Barton; Jeffrey F Patton; John D Zubkus; Lisa Simons; Paula Griner; Howard A Burris; F Anthony Greco
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

4.  Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.

Authors:  E Laack; N Dickgreber; T Müller; A Knuth; J Benk; C Lorenz; F Gieseler; H Dürk; W Engel-Riedel; K Dalhoff; C Kortsik; U Graeven; M Burk; T Dierlamm; T Welte; I Burkholder; L Edler; D K Hossfeld
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

Review 6.  It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.

Authors:  Jason R Westin; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-11-30       Impact factor: 6.261

Review 7.  Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.

Authors:  Anand Rajeswaran; Andreas Trojan; Bernard Burnand; Massimo Giannelli
Journal:  Lung Cancer       Date:  2007-08-27       Impact factor: 5.705

8.  Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.

Authors:  Jean-Louis Pujol; Fabrice Barlesi; Jean-Pierre Daurès
Journal:  Lung Cancer       Date:  2006-02-14       Impact factor: 5.705

9.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

10.  Fool's gold, lost treasures, and the randomized clinical trial.

Authors:  David J Stewart; Razelle Kurzrock
Journal:  BMC Cancer       Date:  2013-04-16       Impact factor: 4.430
View more
  4 in total

1.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Authors:  J Rodon; J C Soria; R Berger; G Batist; A Tsimberidou; C Bresson; J J Lee; E Rubin; A Onn; R L Schilsky; W H Miller; A M Eggermont; J Mendelsohn; V Lazar; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-23       Impact factor: 32.976

2.  A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Authors:  C Anthony Blau; Arturo B Ramirez; Sibel Blau; Colin C Pritchard; Michael O Dorschner; Stephen C Schmechel; Timothy J Martins; Elisabeth M Mahen; Kimberly A Burton; Vitalina M Komashko; Amie J Radenbaugh; Katy Dougherty; Anju Thomas; Christopher P Miller; James Annis; Jonathan R Fromm; Chaozhong Song; Elizabeth Chang; Kellie Howard; Sharon Austin; Rodney A Schmidt; Michael L Linenberger; Pamela S Becker; Francis M Senecal; Brigham H Mecham; Su-In Lee; Anup Madan; Roy Ronen; Janusz Dutkowski; Shelly Heimfeld; Brent L Wood; Jackie L Stilwell; Eric P Kaldjian; David Haussler; Jingchun Zhu
Journal:  J Natl Compr Canc Netw       Date:  2016-01       Impact factor: 11.908

3.  Next-generation companion diagnostics: promises, challenges, and solutions.

Authors:  Joseph D Khoury; Daniel V T Catenacci
Journal:  Arch Pathol Lab Med       Date:  2015-01       Impact factor: 5.534

Review 4.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.